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Rhenium-188-HEDP (
188Re-HEDP) is a new and attractive radiopharmaceutical for the treatment of metastatic bone pain. As a product
of
188W/
188Re generator, it is convenient for clinical therapeutic use with a short physical half-life of 16.9h and a maximal
b-energy of 2.1MeV. We investigated the effect of
188Re-HEDP on pain relief, analgesic intake and impairment of bone marrow function
in 27 patients with bone metastases induced from prostate cancer. All patients were interviewed using a standardised set of questions
before, and after therapy for 12 weeks. The patients were treated with 2700–3459MBq of
188Re-HEDP. Blood samples were taken
weekly for 12 weeks, and a blood count was performed. Patients described an improvement on the Karnofsky performance scale from
7477t o8 5 79% 12 weeks after therapy (P¼0.001). The pain score showed a maximum decrease from 44718 to 27720% in the
third to the eight week after therapy (P¼0.009). Seventy-six percent of the patients described a pain relief without increase of analgesic
intake. Twenty percent of the patients could discontinue their analgesics and were pain free. Mean platelet count decreased from
(286775)*10
3ml
 1 to (215792)*10
3ml
 1, and mean leucocyte count from (7.771.5)*10
3ml
 1 to (6.071.9)*10
3ml
 1 in the
second to the fourth week after therapy. The maximal differences between the values of platelets and leucocytes before and after
therapy were not statistically significant (P¼0.021 and 0.094). In conclusion,
188Re-HEDP is an effective radiopharmaceutical used in the
palliative treatment of metastatic bone pain in prostate cancer and shows minimal bone marrow toxicity.
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Prostate cancer is the second common cause of cancer mortality in
men in the UK and in the US (American Cancer Society, 1991;
Office for National Statistics Series, 1996). Prostate cancer
accounts for 17% of malignant diseases in men 450 years in
Germany (‘Krebsregister in Deutschland’, 1999) with a 5-year
survival rate of 70%.
The skeleton is the most common site for prostatic metastases.
The major mechanism of pain from small metastases appears to be
the stimulation of nerve endings in the endosteum by a variety of
chemical mediators. Larger bone metastases produce stretching of
the periosteum that leads to pain (Nielsen et al, 1991). Resulting
bone pain interferes with the patient’s quality of life and requires
effective treatment. Unfortunately, various nonradiotherapeutic
modalities such as analgesics, hormone therapy, orchidectomy,
cytostatic and cytotoxic drugs, bisphosphonates and surgery are not
effective in all cases, especially in the late stage of the disease
(McEwan, 1998; Debes and Tindall 2002; Gilligan and Kantoff, 2002).
External-beam radiotherapy is suitable only for well-defined
localised bone metastases. Extended field radiation may be useful
in patients with diffuse metastases, but is often accompanied by
serious side effects (Lewington, 1993). Therefore, systemic radio-
nuclide therapy must be considered as a valuable and effective
method of treatment in patients with widespread skeletal metastases.
The various radiopharmaceuticals that are used for palliative
treatment of bone metastases include strontium-89 (Pecher, 1942)
phosphorus-32 (Friedell and Storaassli, 1950), iodine-131-BDP3
(Eisenhut et al, 1986), yttrium-90 (Kutzner et al, 1991), rhenium-
186-HEDP (Maxon et al, 1990) and samarium-153-EDTMP
(Turner et al, 1989). More recently, tin-17m-DTPA (Atkins et al,
1995) rhenium-188-HEDP (Palmedo et al, 2000) and rhenium-188-
DMSA (Blower et al, 2000) have been reported to be effective for
bone pain palliation.
We have had more than 5 years experience in the use of
188Re-
HEDP for the palliative treatment of bone metastases. Rhenium-
188-HEDP has a rapid renal excretion (40712% of administered
activity within the first 8h), leading to a low radiation dose to the
whole body (0.0770.02mGyMBq
 1) and a relative short biological
half-life (51743h) in comparison to the half-life within bone
metastases (2697166h) (Liepe et al, 2003). The favourable
physical characteristics of the radionuclide for its use in palliative
therapy are a short physical half-life of 16.9h and a maximal
b-energy of 2.1MeV with a 15% g-component of 155keV. This
g-component allows the control of tissue distribution after therapy.
As a product from in-house
188W/
188Re generator, similar to a
technetium generator,
188Re-HEDP show a vantage availability.
The long useful shelf-life of the generator leads to lower costs in
comparison to other radiopharmaceuticals like strontium-89,
rhenium-186-HEDP and samarium-153-EDTMP.
MATERIALS AND METHODS
Preparation of
188Re-HEDP
Rhenium-188-HEDP was prepared as previously described by Lin
et al (1997) and Palmedo et al (2000).
188Re-perrhenate was Received 5 December 2002; revised 1 May 2003; accepted 25 May 2003
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lobtained from a 38GBq alumina-based
188W/
188Re generator
(Knapp et al, 1997) (Oak Ridge National Laboratory, Oak Ridge,
USA). The generator was eluted with 20–25ml of 0.9% saline. The
generator eluates were concentrated to about 1.2ml using a
tandem cation/anion concentration system (Guhlke et al, 2000),
which consists of an Ag Plus cartridge (Alltech Associates,
Deerfield, IL, USA) attached to a three-way stopcock connected
at the outlet to the QMA anion trapping column SepPak
s (Waters
Corporation, Milford, MA, USA) anion-exchange column. The
concentration system was housed in a Lucite shield.
In total, 8.3mg HEDP (Fluka Chemie AG, Buchs, Switzerland),
3.0mg gentisic acid (Sigma-Aldrich, Steinheim, Germany) and
3.9mg stannous chloride dihydrate (Merck, Darmstadt, Germany)
were weighed in kit vials and mixed with 1.0ml of carrier-added
188Re-generator eluate (10ml ReO4 Aldrich, 100mmolml
 1
physiological saline). The solution was heated at 96–1001C
for 15min. After cooling to room temperature, 1ml of a sterile
0.3 M sodium hydroxide solution was added to adjust the pH to a
range of 5–6.
Quality control of carrier-added
188Re-HEDP was performed
with thin layer chromatography using silica gel (ITLC-SG) strips
(Gelman, Ann Arbor, MI, USA). In addition, anion exchange
chromatography based on gradient elution with increasing
concentrations of NaCl solutions using a QMA SepPak
s was used.
The radiochemical purity determined by both procedures (ITLC
and ion exchange) was more than 90%. Sterility and pyrogenicity
tests were performed for each preparation.
Patients
In this phase II study, 27 patients with multiple bone metastases
from prostate cancer and pain well-controlled by conventional
analgesia were included. In previous dose-escalation studies
(Palmedo et al, 2000), an activity of 3300MBq of
188Re-HEDP
was determined as suitable for bone pain palliation. We evaluated
the effect of
188Re-HEDP on pain relief, reduction of analgesics and
changes in quality of life. Before and for 12 weeks after the
188Re-
HEDP therapy, weekly interviews with a standardised set of
questions concerning pain relief with the visual analogue scale
(VAS) from 0 to 100% (Serafini et al, 1998; Kraeber-Bodere et al,
2000), analgesics and Karnofsky performance scale were con-
ducted weekly (Figure 1). A pain relief p25% on the VAS at least
in two consecutive weeks without increase of analgesics was used
as criteria for response.
Blood counts were obtained to evaluate the impairment of bone
marrow function within 6 weeks after therapy and in the 12th
week. For the assessment of toxicity, the toxicity criteria of the
World Health Organization (1979) were used. According to this
toxicity scale, platelet counts of 74–99*10
9l
 1,5 0–7 4*10
9l
 1,2 5–
49*10
9l
 1 and below 25*10
9l
 1 correspond to a toxicity grade of
1, 2, 3 and 4, respectively. The maximum decrease was calculated
by comparison of the level of blood counts before therapy
(baseline) with the lowest level within 12 weeks. All patients
underwent a
99mTc-HMDP bone scan within 1 month before and 3
months after therapy to obtain a possible decrease of the mass of
bone metastases. In a single case, we had also a later bone scan.
Criteria for patient inclusion in the study were
  positive
99mTc-HMDP bone scan with at least three lesions;
  bone pain symptoms requiring the long-term use of analgesics;
  sufficient bone marrow function with a platelet count
X100 10
3ml
 1, leucocyte count X3.0*10
3ml
 1 and haemoglo-
bin X6.0mmoll
 1 (9.67gdl
 1);
  normal renal function.
Criteria for exclusion were
  metastatic bone fractures;
  spinal cord compression;
  soft tissue tumours elsewhere causing nerve compression.
Chemotherapy and bisphosphonate therapy were discontinued 4
weeks before the administration of the radiopharmaceutical. In
accordance with the Helsinki declaration, all patients were
informed comprehensively about the study and possible side
effects and were provided with a leaflet. Consent approval had
been obtained from the local ethics committee.
Statistics
Data are presented as mean7s.d. For determining a significant
change in the visual analogue scale and Karnofsky performance
scale, we used the Student’s t-test. Two-tailed P-values less than
0.05 were considered to indicate statistical significance.
RESULTS
Twenty-seven patients (mean age¼68, range 55–87 years) with
disseminated bone metastases from prostate cancer received a
single intravenous injection of
188Re-HEDP. The administered
activity ranged from 2700 to 3587MBq (mean do-
se¼32457356MBq). All patients had analgesics. Patients were
hospitalised for 2 days for the
188Re-HEDP therapy due to
regulations in the German radiation protection law. All patients
had a single therapy. All patients received a hormone therapy for at
least 6 months before therapy and also during the post-therapy
observation period. Nineteen patients had been treated with a
bisphosphonate for at least 6 months, this was discontinued four
weeks before therapy. In addition, five patients received
chemotherapy and seven patients external beam radiation prior
to the
188Re-HEDP therapy. All these treatments were finished at
least 5 months before the
188Re-HEDP therapy. It is unlikely that
these various preceding therapies modified or altered the observed
therapeutic effect in this study.
Twenty-five patients were included in the evaluation of the
therapeutic efficiency of the
188Re-HEDP therapy. Two patients
were excluded: one patient because of incomplete follow-up and
one died 9 weeks after treatment from the cancer, unrelated to the
therapy.
The Karnofsky performance scale increased from 7477% before
therapy to 8579% at 12 weeks after therapy (Figure 1). This
increase was statistically significant (P¼0.001). Pain relief p25%
on the VAS at least in two consecutive weeks without increase of
analgesics intake was achieved in 76% of patients (19 out of 25).
Five from these 19 patients were pain free (20%). The VAS showed
a decrease from 44718 to 31725% at the 12th week after
188Re-
HEDP therapy (P¼0.009) (Figure 2). The maximum of pain relief
was described within the 3rd to the 8th week (27720%).
There was no evidence of either local or systemic intolerance to
treatment with
188Re-HEDP, while a flare reaction with an increase
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Figure 1 Time course of the Karnofsky performance scale before and
within 12 weeks after
188Re-HEDP therapy (with s.d.’s).
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Most of the patients showed a grade I anaemia according to the
WHO criteria (World Health Organization, 1979) before injection,
with no significant worsening within 12 weeks after therapy
(haemoglobin 7.672.6 before and 7.173.0mmoll
 1 12 weeks after
treatment). The maximum decrease in one patient from the
baseline value was 6.8 to 5.7mmoll
 1. There was mild thrombo-
cytopaenia (grade I thrombocytopaenia in two patients and grade
II in one patient), but no evidence of unacceptable toxicity
(defined as grade III or IV toxicity). Thrombocytopaenia was
reversible within 12 weeks after therapy. The platelet counts
decreased from a baseline value of 286775*10
9l
 1 to a maximum
of 218783*10
9l
 1 at 2.770.9 weeks after therapy (Figure 3). The
patient with a thrombocytopaenia grade II had a platelet count of
62*10
9l
 1. Grade I leucopenia was observed only in one patient
(2.9*10
9l
 1) and was also reversible within 12 weeks. The
leucocyte counts decreased from a baseline value of
7.471.5*10
9l
 1–6.071.9*10
9l
 1 at 3.070.6 weeks after therapy
(Figure 4).
Generally, over the follow-up period, there were no significant
changes in the PSA levels, but in individual cases a decrease was
noted (PSA level: 1597151 vs 1557203ngml
 1; P¼0.96).
No patient showed a decrease in the bone metastases demon-
strated on the
99mTc-HMDP bone scans before treatment when
compared to the scans obtained 3 months post-treatment. The
bone scan index (BSI) level (Blake et al, 1986) in the group of
patients with no response to the
188Re-HEDP therapy was 54719,
in the group of patients with a good response 37714 and in pain-
free patients 3675( P¼0.24). In three of the patients, there was a
decrease of the number of bone metastases with a mean decrease of
the BSI level from 33718 before treatment to 19711 within 1 year
after
188Re-HEDP therapy. One of these showed an improvement of
the BSI from 45 to 17 six months after therapy (Figure 5A, B). The
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Figure 2 Time course of the pain at visual analogue scale before and
within 12 weeks after
188Re-HEDP therapy (with s.d.’s).
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Figure 3 Bone marrow impairment due to
188Re-HEDP expressed as
platelet counts in serial blood samples (with s.d.’s).
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Figure 4 Bone marrow impairment due to
188Re-HEDP expressed as
leucocyte counts in serial blood samples (with s.d.’s).
R
R
R R
L
L
L L
RELAT
LILAT
Anterior Posterior
Tc−99m−HMDP
2h p.i.
R R L L
RELAT
LILAT
Anterior Posterior
Tc−99m−HMDP
2h p.i.
A
B
Figure 5 (A) Bone scan of a 71-year-old patient with bone metastases
induced by prostate cancer one month before
188Re-HEDP therapy (bone
scan index¼45). The Karnofsky performance scale was 70% and the pain
of the visual analogue scale¼50%. (B) Bone scan of the same patient 6
months after therapy (bone scan index¼17). The Karnofsky performance
scale was 80% and the pain of the visual analogue scale¼25%.
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etidronacid), nonsteroid antiandrogen (flutimide), progestagen
(megestrolacetate) and an analogue of the luteinising hormone
(goserelineacetate) from the beginning of the disease. Under this
therapy, the patient described a progression of the disease with an
increase in pain symptoms. Within 12 weeks of the
188Re-HEDP
therapy, the Karnofsky performance scale increased from 70 to
80%, and the pain at the VAS decreased from 50 to 25%.
DISCUSSION
Systemic radionuclide therapy with b-emitting radiopharmaceu-
ticals represents a therapeutic option in the management of
intractable metastatic bone pain and has been used since 1942
(Pecher, 1942). Nowadays, strontium-89, rhenium-186-HEDP and
samarium-153-EDTMP are the preferred radiopharmaceuticals.
From a theoretical point of view,
188Re-HEDP offers potential as a
new and attractive radiopharmaceutical for the treatment. As a
generator product it has an excellent availability that permits on-
site labelling as with the routinely used
99mTc-generator resulting
in low costs.
In the literature there are few reports about the therapeutic
efficiency of
188Re-HEDP in only small patient groups (Maxon et al,
1998; Palmedo et al, 2000), which reported a response rate of 70–
80%. In 23 patients with bone metastases from a variety of primary
tumours,
188Re-HEDP therapy was able to reduce analgesic intake
in 82% of patients (Chen, 2000). In addition, 70% of the patients
had a significant and 22% a minor improvement of quality of life.
Using
188Re-HEDP at an activity of 1100MBq, a response rate of
80% was obtained in a cohort of 61 patients with various primary
tumours (Li et al, 2001). Studies with a large number of patients
exist for patients treated with strontium-89, rhenium-186-HEDP
and samarium-153-EDTMP. In a multicentre study with 818
patients treated with strontium-89 and rhenium-186-HEDP
Dafermou et al (2001) described pain relief in 81% of the patients
with prostate cancer and 27% of these were pain free. Enrique et al
(2002)showed a response rate of 73% in a cohort of 417 patients
treated with samarium-153-EDTMP at an activity varying between
18.5 and 55MBqkg
 1 body weight. In our study using
188Re-
HEDP, pain relief was demonstrated in 76% of patients and 20%
from these were pain free without increase of analgesia. In
addition, a significant increase of the Karnofsky performance scale
of 11% compared to the initial value within 12 weeks was observed.
In comparison, the dose-escalation study in a small number of
patients (n¼6) using 3300MBq of
188Re-HEDP (Palmedo et al,
2000) showed a lower response rate.
In the present study, no unacceptable toxicity was observed.
There were two patients with thrombocytopaenia grade I and one
with thrombocytopaenia grade II. A mean decrease of platelet
counts of 30714% from the baseline value was noticed, maximally
at 2.770.9 weeks after therapy. The maximum decrease in one
patient was down to 62*10
9l
 1. The leucocyte counts showed a
mean decrease of 25717% from the baseline value (Figure 4) with
a maximum at 3.070.6 weeks. Only one patient had a leucopenia
grade I. The bone marrow toxicity of
188Re-HEDP showed no
correlation to the extension of bone metastases in the
99mTc-
HMDP bone scan or the level of the BSI. Similar results are shown
in the dose-escalation study with 3300MBq
188Re-HEDP of
Palmedo et al (2000), who observed two patients with thrombo-
cytopaenia grade I and one with grade II. In the group with
4400MBq, an unacceptable toxicity was observed in three out of
eight patients, two with thrombocytopaenia grade IV and one with
thrombocytopaenia grade III. Therefore, an activity of 3300MBq of
188Re-HEDP is generally accepted in the palliative treatment of
bone metastases.
The mean PSA level was unchanged during the follow-up
(1597151 vs 1557203ngml
 1; P¼0.96, but in individual cases
there was a measurable decrease in the PSA.
While radionuclide therapy for bone pain is mainly palliative,
occasionally cure can be obtained and in the three cases described
in this study there were decreases in bone metastases shown on
conventional
99mTc-HMDP bone scan with concomitant decrease
in the BSI level from 33718 to 19711 within 1 year after
treatment (Robinson et al, 1989; Mertens et al, 1992; Liepe et al,
2000). Of these patients, two were pain free.
In general, large bone metastases demonstrated on the
99mTc-
HMDP bone scans correlate well with sites of pain. In patients
where there was no response to therapy, a higher BSI level was seen
(BSI¼51719) compared to those patients where a favourable
response occurred or the patients were pain free (BSI¼33711)
(P¼0.08). Other authors also described a higher response rate to
treatment in early bone metastases, favouring active treatment in
such cases (Kraeber-Bodere et al, 2000; Dafermou et al, 2001).
A previous dosimetry study gave the radiation absorbed dose for
188Re-HEDP as 11.876.2Gy (range: 1.2–31.3Gy) for the bone
metastases, and 1.970.7Gy (1.3–3.6Gy) for the red bone marrow
(Liepe et al, 2003). These values are comparable with the dosimetry
for
186Re-HEDP (26Gy for the bone metastases and 1.8Gy for
the red bone marrow) and also with the therapeutic effect and
the bone marrow toxicity of
186Re-HEDP (Maxon et al, 1990,
1998).
In conclusion,
188Re-HEDP is effective in the palliation of
metastatic bone pain, without induction of severe side effects.
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